Moonwalk Biosciences

We’re excited to announce the launch of Moonwalk Biosciences, a genomic medicine company pioneering precision epigenetic medicines, with $57 million in financing from Alpha Wave Global, ARCH Venture Partners, Future Ventures, GV (Google Ventures), Khosla Ventures and YK Bioventures. By targeting the epigenetic code – the software of the genome – Moonwalk aims to reprogram cells to their healthy state, fundamentally enabling a new approach to how therapies are discovered and developed. Moonwalk is the first company that couples an epigenetic discovery platform with precise engineering – opening up the epigenome as a new target space for complex diseases. Learn more here: https://moonwalk.bio/ Read our press release: https://lnkd.in/gcuF7Umy More info about us in: WSJ: https://lnkd.in/e5_6R2y2 STAT: https://lnkd.in/eViTRJqE Endpoints News: https://lnkd.in/eSySAyWd Biopharma Dive: https://lnkd.in/ei8wKM2n

Rigel Kishton did a great job presenting Moonwalk’s first data on an epigenetic atlas of adipocytes at ObesityWeek? 2024 in San Antonio! #obesityweek

Excited to announce that we will present new data using our #epigenetic technology at two upcoming scientific conferences, The Liver Meeting? 2024, hosted by the American Association for the Study of Liver Diseases (AASLD) and ObesityWeek? 2024, organized by The Obesity Society. Moonwalk will present new data highlighting its epigenetic capabilities in identifying new therapeutic targets for metabolic diseases and liver disorders using its proprietary EpiRead? and EpiWrite? platforms. Details of the presentations are as follows: ObesityWeek 2024 Oral Presentation Title: A Comprehensive Epigenetic Atlas of Human Adipocytes Date/Time: Monday, November 4, 9:15 - 9:30 AM Location: Room 207 The Liver Meeting 2024 Presentation Title: Elucidating Novel Therapeutic Targets for Metabolic Disease Through High Resolution Epigenetic Profiling of Primary Human Adipocytes Poster number: 1079 Date/Time: Friday, November 15, 1:00 - 2:00 PM Location: Hall C Read the full release: ???? https://lnkd.in/ej6g8rk3

Our Chief Business Officer Elaine Cheung will be speaking on a panel tomorrow at BIO Investor Forum in SF! ???? While the rate of IPOs this year is slightly increased versus 2023, the market is still much less active since 2021 and hoping the Q3 interest rate cut of 0.5% sparks additional investor support. This session will examine how private company CEOs should be preparing now for the types of IPOs that will be best received by the public markets, along with the implications for any opportunistic secondary offerings, amid an era of heightened geopolitical and market volatility. Moderator Jakob Dupont, MD MA, Executive Partner - Sofinnova Investments Speakers Emily P. - MD, Principal - DCVC Bio Carolyn Ng - PhD, Partner and Managing Director - TPG Life Sciences Innovations Elaine Cheung, Chief Business Officer - Moonwalk Biosciences Pete Garcia, Chief Financial Officer - ALX Oncology Colin Walsh, PhD -Managing Director, Growth Equity, Goldman Sachs View the agenda: ???? https://lnkd.in/dT3zhgkY

“We're opening up the epigenome as a platform for drug discovery.” Moonwalk Biosciences is a biotech company devoted to pioneering precision epigenetic medicines. This week on Translating Aging, CEO & co-founder Alex Aravanis MD PhD tells us about Moonwalk’s mission to harness the power of epigenetics to develop a new class of medicines aimed at treating complex diseases and potentially extending human healthspan. Translating Aging is produced by BioAge Labs, a clinical-stage biotechnology company that is harnessing the biology of human aging to develop novel targets and therapies for metabolic diseases. Episode: https://lnkd.in/g6XtThZK (click ‘FOLLOW’ for links to your favorite podcast platform) Podcast: https://lnkd.in/gvF4X-ka

Our CBO Elaine Cheung was on a panel at LSX USA Congress in Boston today on Cultivating Success: Establishing an Outstanding Biotech Executive team. The panel was moderated by Leslie Loveless at Slone Partners and also featured Michael Curtis from eGenesis, Inc., Lihua Zheng JD PhD , and Curie.Bio. Fantastic discussion and great to see everyone there! ????

Looking forward to visiting Boston this week, and engaging with colleagues and potential partners!

"Pioneering precision epigenetic medicines." Moonwalk Biosciences is revolutionizing the development of therapies by targeting the epigenome, using advanced AI and engineering tools to reprogram cells for treating complex diseases at their root cause. Learn more:?https://moonwalk.bio #Epigenetics #BiotechInnovation?#SoHCSpotlights

Moonwalk Biosciences Appoints Dr. John Liles as VP Biology and Translational Science; Forms Cardiometabolic Advisory Board Learn more & get our take ?? https://lnkd.in/gdCc5FhH “We are thrilled to welcome John to our team and announce the formation of our cardiometabolic advisory board. John’s expertise in translating innovative therapeutics from discovery through IND will accelerate our ambitious R&D efforts.” — Alex Aravanis MD PhD, Co-founder & CEO at Moonwalk Biosciences “I’m excited to join the Moonwalk team at a pivotal time as the company advances its preclinical efforts to pioneer new insights about epigenetic biology and engineering cell state.” — John Liles, Ph.D., VP Biology and Translational Science at Moonwalk Biosciences #leadership #biology #SoHCNews

We’re excited to welcome John Liles, Ph.D., VP Biology and Translational Science to the Moonwalk team and the formation of a world class Cardiometabolic Advisory Board. Dr. Liles brings deep experience as a drug discovery biologist with proven success advancing novel therapeutics from target discovery through IND for liver, kidney, lung and #cardiovascular diseases. “We are thrilled to welcome John to our team and announce the formation of our cardiometabolic advisory board,” said Alex Aravanis MD PhD, M.D., Ph.D., Co-founder & CEO, Moonwalk Biosciences, “John’s expertise in translating innovative therapeutics from discovery through IND will accelerate our ambitious R&D efforts.” Moonwalk will be presenting data and providing an update at future scientific meetings, including an oral presentation at ObesityWeek? 2024 and a poster presentation at American Association for the Study of Liver Diseases (AASLD) 2024. Read the release: https://lnkd.in/eQK6Uk6G